Eupraxia Pharmaceuticals (EPRX) Fireside Chat - EUPRAXIA PHARMACEUTICALS INC

Financial Performance:

• No specific revenue, earnings, profit margin, cash flow, or debt figures were disclosed as the company is a clinical-stage biotech currently in Phase 2 trials.
• The company operates with a pre-revenue business model, relying on funding to support clinical development rather than commercial sales.

Guidance and Future Outlook:

• Primary catalyst: Interim data readout from the Phase 2b randomized study scheduled for early December.
• Future timeline: Baseline patient characteristics to be released in mid-November; study design includes extending follow-up to 2 years to determine repeat-dosing intervals for NDA alignment.
• Market expansion goal: Potential to address earlier disease stages (mild histology) to stop fibrosis progression, significantly increasing Total Addressable Market (TAM) by targeting patients currently on PPIs.
• Regulatory pathway: Anticipates FDA endpoints to shift from eosinophil count (surrogate) to histologic outcomes (EOHSS) combined with patient-reported outcomes (DSQ).

Business Segments and Product Lines:

• Lead asset: EP104GI (fluticasone propionate) for Eosinophilic Esophagitis (EOE).
• Mechanism: Submucosal injection during annual endoscopy to deliver corticosteroid directly to tissue, providing upstream inhibition of Type 2 inflammation (IL-13, IL-5, IL-4) and anti-fibrotic effects.
• Dosing strategy: Phase 2b testing two doses (120mg and 160mg total), with design focusing on durability and a one-year treatment window.
• Clinical differentiation: Maintains 64% clinical remission at 52 weeks in dose-escalation studies, contrasting with high eosinophil remission but low clinical remission seen in prior therapies (e.g., tezepelumab/alirocizumab examples).

Market and Competitive Landscape:

• Disease epidemiology: EOE prevalence estimates updated from ~150,000 to 450,000–550,000, projected to reach ~1 million in the US by 2030.
• Competitive set: Dupixent (Dupilumab) is the only approved long-term therapy; recent data shows 76,000 patients treated since 2022 launch (10 months ago).
• Market positioning: EP104 targets the gap between PPI/diet therapy and biologics (post-PPI, pre-biologic), aiming to replace non-compliant oral steroid regimens.
• Pricing strategy: Third-party analysis suggests a target price point of ~$50,000, aligning with efficacy expectations and duration of effect (9+ months).

Risks and Challenges:

• Clinical trial complexity: Disconnect between histologic response (eosinophil reduction) and clinical symptoms creates difficulty in defining primary endpoints; eosinophil count may not be FDA-accepted as a primary surrogate.
• Patient selection: Efficacy may vary based on disease severity; inclusion of mild histology patients in the trial adds complexity to early data interpretation.
• Market adoption: High baseline noise in Patient-Reported Outcomes (DSQ) metrics may require large effect sizes to achieve statistical significance compared to other therapies.
• Competitive pressure: Rapid patient uptake by Dupixent (growing from 54k to 76k in 10 months) indicates strong demand for long-term solutions, though penetration remains low.

Management Commentary and Tone:

• Tone: Confident and strategic, emphasizing a "move upstream" approach to inflammation and fibrosis rather than solely targeting eosinophils.
• Leadership: CEO James Helliwell highlighted the unique value proposition of guaranteed compliance via physician-administered injections and long-term histologic durability.
• Confidence in data: Management expressed strong belief in the durability of effects (maintained at 9 months in prior studies) and the potential for the drug to alter the treatment paradigm by preventing fibrosis.

Analyst Questions and Answers:

• Endpoint Clarification: Confirmed that the Dysphagia Symptom Questionnaire (DSQ) is likely the primary PRO, while EOHSS (histologic scoring) is expected to become the preferred histologic endpoint over eosinophil counts.
• Study Design: Detailed the Phase 2b structure: 3 arms (Vehicle, 120mg, 160mg), 40 patients per arm, with a planned crossover for the control arm at 6 months and extended follow-up to 2 years.
• Statistical Power: Interim readout (6 months) aims for 80% power to detect a 1.2-point DSQ difference; 70% power to detect a 10-point improvement over placebo.
• Market Data: Provided specific Dupixent patient growth metrics (54,000 to 76,000 in 10 months) to contextualize market traction.
• Upcoming Data: Clarified that baseline characteristics will be released in mid-November to frame the December interim results.

Other Key Points:

• The study includes patients with mild histology but moderate symptoms to assess if early treatment can halt fibrosis progression, a concept not currently powered in Phase 3.
• Management expects the Phase 2b trial to generate data supporting a NDA (New Drug Application) with patients receiving multiple doses over several years.
• The treatment addresses a major adherence issue in current standard-of-care oral steroids, which suffer from high non-compliance rates leading to rapid symptom/fibrosis recurrence.